CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: CT-322 may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping
blood flow to the cancer.
PURPOSE: This phase I trial is studying the side effects of CT-322 in treating patients with
advanced solid tumors or non-Hodgkin's lymphoma.